Research Article

Urinary prostaglandin E₂ as a biomarker for recurrent UTI in postmenopausal women

Tahmineh Ebrahimzadeh¹, Amy Kuprasertkul², Michael L Neugent¹, Kevin C Lutz³, Jorge L Fuentes², Jashkaran Gadhvi¹ , Fatima Khan¹, Cong Zhang³, Belle M Sharon¹, Kim Orth^{4,5,6}, Qiwei Li³, Philippe E Zimmern², Nicole J De Nisco¹

Urinary tract infection (UTI) is one of the most common adult bacterial infections and exhibits high recurrence rates, especially in postmenopausal women. Studies in mouse models suggest that cyclooxygenase-2 (COX-2)-mediated inflammation sensitizes the bladder to recurrent UTI (rUTI). However, COX-2-mediated inflammation has not been robustly studied in human rUTI. We used human cohorts to assess urothelial COX-2 production and evaluate its product, PGE₂, as a biomarker for rUTI in postmenopausal women. We found that the percentage of COX-2-positive cells was elevated in inflamed versus uninflamed bladder regions. We analyzed the performance of urinary PGE₂ as a biomarker for rUTI in a controlled cohort of 92 postmenopausal women and PGE₂ consistently outperformed all other tested clinical variables as a predictor of rUTI status. Furthermore, time-to-relapse analysis indicated that the risk of rUTI relapse was 3.6 times higher in women with above median urinary PGE₂ levels than with below median levels. Taken together, these data suggest that urinary PGE₂ may be a clinically useful diagnostic and prognostic biomarker for rUTI in postmenopausal women.

DOI [10.26508/lsa.202000948](https://doi.org/10.26508/lsa.202000948) | Received 26 October 2020 | Revised 21 April 2021 | Accepted 26 April 2021 | Published online 6 May 2021

Introduction

Urinary tract infection (UTI) affects more than 150 million people annually worldwide (Stamm & Norrby, 2001; Flores-Mireles et al, 2015). UTIs are a leading indication for prescription antibiotics and have a significant impact on women of all ages (Amna et al, 2013). Recurrent urinary tract infection (rUTI) is defined as ≥ 3 symptomatic UTIs in 12 mo or ≥ 2 symptomatic UTIs in 6 mo (Nicolle, 2001; Glover et al, 2014; Malik et al, 2018b). rUTI has a severe impact on quality of life causing pain, frequency, urgency, anxiety, and symptoms of clinical depression among affected women (Ellis & Verma, 2000; Renard et al, 2014). rUTI incidence increases with age with reported recurrence rates as high as 50% in postmenopausal women (Foxman, 2002, 2014; Raz, 2011). rUTI is caused by diverse bacterial species and less commonly by

fungi (Flores-Mireles et al, 2015). The front-line therapy for rUTI is prescription of antibiotics such as trimethoprim sulfamethoxazole, nitrofurantoin, and fluoroquinolones (Jancel & Dudas, 2002). Resistance, allergy, or documented adverse reactions to antibiotics are frequent in the elderly and limit the safety and efficacy of antibiotics in this demographic (Jancel & Dudas, 2002; Malik et al, 2018a). Therefore, new therapies for rUTI must be developed.

rUTI is, in part, an inflammatory disease (Bjorling et al, 2011). Evidence of chronic inflammation has been reported in the bladders of rUTI patients during cystoscopy (Wu et al, 2016; Crivelli et al, 2019). Extensive work performed exclusively in mouse models has implicated host inflammation, specifically Cyclooxygenase-2 (COX-2)-mediated inflammation, as a key sensitizing factor for rUTI (Hannan et al, 2010; Hannan et al, 2014; O'Brien et al, 2016). Excessive urothelial neutrophil infiltration and COX-2-dependent inflammation were found to cause tissue damage and remodeling that sensitize the bladder to severe rUTI (Hannan et al, 2014; O'Brien et al, 2015; O'Brien et al, 2016). Importantly, Hannan et al (2014) demonstrated that treatment of mice with specific COX-2, but not COX-1, inhibitors protected the bladder against sensitization to severe rUTI (Hannan et al, 2014). Furthermore, treatment of mice with dexamethasone, another drug targeting the COX-2 pathway, suppressed development of chronic cystitis (Hannan et al, 2010). These data suggest that the COX-2 pathway may be a promising therapeutic target for rUTI; however, knowledge of the role of COX-2-mediated inflammation in human rUTI is limited.

Here, we used defined, well-curated human cohorts to evaluate activation of the COX-2-mediated inflammation during rUTI in postmenopausal women. We hypothesized that, as observed in mouse models of UTI, COX-2 would be expressed in urothelium of visibly inflamed bladder regions in human rUTI patients. To determine if COX-2 enzyme levels are elevated in regions of cystitis, we enumerated COX-2-expressing urothelial cells in bladder biopsies from inflamed and control regions. We assessed urinary PGE₂ as a proxy for urothelial COX-2 expression in matched bladder biopsy and urine samples. We then evaluated PGE₂ as a biomarker for rUTI in postmenopausal women by measuring urinary PGE₂ levels across three groups with different UTI histories. Finally, we

¹Department of Biological Sciences, University of Texas at Dallas, Richardson, TX, USA ²Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA ³Department of Mathematics, University of Texas at Dallas, Richardson, TX, USA ⁴Department of Molecular Biology, University of Texas Southwestern Medical Center, Dallas, TX, USA ⁵Howard Hughes Medical Institute, University of Texas Southwestern Medical Center, Dallas, TX, USA ⁶Department of Biochemistry, University of Texas Southwestern Medical Center, Dallas, TX, USA

Correspondence: nicole.denisco@utdallas.edu

performed a time-to-relapse study to determine if urinary PGE₂ levels were predictive of rUTI relapse.

Results

COX-2 expression is activated in the bladder urothelium during human rUTI

Previous work in mouse models has demonstrated that COX-2 expression triggers prolonged neutrophil recruitment resulting in

tissue damage, changes to bladder wall morphology, and increased susceptibility to severe rUTI (Hannan et al, 2014; O'Brien et al, 2016; Yu et al, 2019). To determine if COX-2 expression was activated during human rUTI, we analyzed COX-2 expression and neutrophil recruitment in bladder urothelium in two cohorts of women undergoing cystoscopy with fulguration of trigonitis (CFT). For Cohort 1, antibiotic therapy was stopped after symptom resolution 7 d before CFT, and two biopsies, one from a visibly inflamed (I1) and one from a visibly normal control region (C1) of the bladder, were obtained (Fig 1A) (De Nisco et al, 2019). To determine if COX-2 expression was associated with neutrophil recruitment, we visualized COX-2 and

Figure 1. COX-2 expression is activated in the bladder urothelium during human recurrent urinary tract infection.

(A) Cohort 1 patient recruitment and procedure timeline. (B) Representative confocal micrographs (63×) of I1 and C1 regions of PNK006 and PNK011 with DNA (Hoechst) in blue, Mucin (WGA) in green, COX-2 in red and neutrophils (ELA-2) in magenta. Scale bar represents 10 μm. (C, D) Quantification of COX-2 expressing cells and (D) neutrophils within the urothelium of control (blue) and inflamed (red) region biopsies reported as percentage of total urothelial cells. 10 randomly sampled images were enumerated for each section. Bar graphs represent mean ± SEM. (E) Comparison of %COX-2-expressing cells and %neutrophils between control and inflamed regions. Whiskers drawn minimum to maximum, boxes represent interquartile range, and median denoted by horizontal line. P-values generated by Wilcoxon matched pairs signed-ranks test. (F) Linear regression with Spearman correlation between %neutrophils and %COX-2-positive cells.

elastase (ELA2), a neutrophil marker (Lammers et al, 1986), in the I1 and C1 regions using immunofluorescence (IF) confocal microscopy (Figs 1B and S1). COX-2-positive urothelial cells were not observed in every I1 biopsy. Representative images of I1 biopsies with high urothelial COX-2 (PNK006) versus undetectable urothelial COX-2 (PNK011) are presented in Fig 1B. Quantification of COX-2-expressing urothelial cells and neutrophil infiltration was performed and reported as percentage of total of urothelial cells (Fig 1C and D). Urothelial COX-2 expression was observed in the I1 regions of 85.7% (12/14) of patients (Fig 1B and C). Similarly, neutrophil infiltration was observed in the I1 regions of 71.4% (10/14) of patients (Fig 1B and D). The quantification data for COX-2 and neutrophils were summarized and classified into two groups: inflamed and control. The median percentage of urothelial COX-2-expressing cells and neutrophils was 6.1 and 24.1 times higher in inflamed versus control regions, respectively (Fig 1E). Correlation analysis between neutrophil infiltration and COX-2-expressing cells in the I1 area revealed a strong correlation between the two inflammatory markers ($r_s = 0.8877$, $P = 0.00006$) (Fig 1F). In these biopsies we defined the suburothelium as the region underlying the urothelium that includes the lamina propria and in some cases the muscularis propria. Suburothelial neutrophil accumulation was found in patients PNK003, PNK006, PNK010, PNK011, and PNK014, indicating that neutrophil accumulation was not limited to the urothelium (Fig S2A–E). Suburothelial COX-2 expression was also observed but predominately in regions with severely damaged urothelium or colocalized with neutrophils (Fig S2A, C, E, and F).

Urinary PGE₂ as a marker for COX-2-mediated bladder inflammation

We next sought to identify a marker of COX-2 activity that would be measurable in urine. Prostaglandin E₂ (PGE₂) is the product of arachidonic acid conversion by the COX-2 enzyme (Ricciotti & FitzGerald, 2011). Extracellular PGE₂ elicits diverse cellular responses including cell proliferation, angiogenesis, pain sensation, and inflammation (Nakanishi & Rosenberg, 2013; Kawahara et al, 2015). Induced COX-2 expression results in higher secreted levels of PGE₂ (Wheeler et al, 2002; Park et al, 2006). Therefore, we hypothesized that urinary PGE₂ should be a reliable indicator of urothelial COX-2 expression (Wheeler et al, 2002). To test this hypothesis, we measured both urothelial COX-2 expression and urinary PGE₂ in a second CFT cohort (Cohort 2, PNK016–27) (Fig 2A). For this cohort, due to changes in the IRB-approved protocol, antibiotic therapy was not ceased before CFT and one inflamed-region biopsy (I1) was obtained. Cohort 2 patient statistics and clinical urine culture (UC) results are reported in Table 1.

We performed IF for COX-2 and neutrophils on I1 bladder biopsy tissues and commercially available normal bladder biopsy sections as a control (US Biomax). Representative images of control, PNK025 and PNK027 biopsy sections are shown in Figs 2B and S3. COX-2 expressing urothelial cells or neutrophils were counted and reported as percentage to total number of urothelial cells (Fig 2C and D). PNK025 and PNK027 biopsy sections showed the highest median percentages of COX-2 expressing cells (16.5% and 33.5%, respectively) (Fig 2C). Urothelial neutrophil infiltration was found in PNK016 and PNK023–27 but was highest in PNK025 (median = 21.9%)

and PNK027 (median = 18.5%), mirroring the high percentage of COX-2-expressing cells detected in these biopsies (Fig 2D).

We next measured urinary PGE₂ levels. To control for differences in urine concentration, urinary biomarkers are often normalized to creatinine (Cr). Urinary creatinine excretion rate is assumed to remain constant within and between individuals; however, recent reports indicate that urinary creatinine excretion rate may vary widely between individuals depending on different clinical factors (Tang et al, 2015). Accordingly, Tang et al (2015) suggest both normalized and non-normalized data should be reported. Urinary PGE₂ concentration is presented normalized to creatinine (Fig 2E) and in raw values (Fig 2F). To determine if urinary PGE₂ is associated with urothelial COX-2 expression, we performed linear regression analysis between PGE₂ concentration and percentage of COX-2-positive urothelial cells and observed a robust positive association between urinary PGE₂ concentration and percentage of urothelial COX-2-expressing cells ($r_s = 0.8818$, $P = 0.0007$) (Fig 2G). Urinary PGE₂ levels were highest in PNK016, 23, 25, and 27 (Fig 2F and G). Although the urinary PGE₂ concentration of PNK016 was high (2,670.7 pg/ml), the percentage of COX-2-positive urothelial cells and neutrophils was relatively low in the biopsied tissue (Fig 2C and D). Because the selection of inflamed region biopsied was based on visible cues, one possible explanation is that the inflamed region biopsied for this patient was not representative of the bladder as a whole and regions with high numbers of COX-2-positive cells or neutrophils were not captured in the biopsy. For this reason, analysis of PGE₂ concentrations in the urine, which is less prone to sampling bias, is important. Interestingly, three of the patients with high urinary PGE₂ concentrations (PNK016, 23, and 27) were the only patients in this cohort who presented with positive UC on the day of CFT (Table 1).

Although sample size is low, one possible interpretation is that urinary PGE₂ levels are associated with bacteriuria. We observed a single outlier, PNK025, which was UC negative. We hypothesized that although antibiotics had eliminated urinary bacteria, bacteria may still be present within the bladder wall. To test this hypothesis, we performed FISH with a 16S rRNA universal bacterial probe on all Cohort 2 biopsies (Neugent et al, 2019). Representative images demonstrate the presence of tissue-associated bacteria in the bladder wall of PNK025 and PNK027 (Fig 3A). Quantification of bacterial community size revealed the largest load of tissue-resident bacteria in PNK025 (Fig 3B), suggesting that although the UC for PNK025 was negative, there was a high burden of tissue-resident bacteria (Fig 3A and B). In accordance with previously published observations, we detected suburothelial bacterial communities in the bladder wall of several patients including PNK016–19, 22, 25, and 26 (Figs 3B and S4). Taken together, higher urinary PGE₂ levels were associated with urothelial COX-2 expression as well as with a higher bacterial load either in the urine or bladder wall.

PGE₂ is elevated during rUTI relapse but not during remission

Previous studies have shown that expression of the gene encoding COX-2, *Ptgs2*, was elevated 24 h postinfection in rUTI-sensitized mice but did not remain elevated during convalescence (Hannan et

Figure 2. Urinary PGE₂ as a marker for COX-2-mediated bladder inflammation.

(A) Cohort 2 patient recruitment and procedure timeline. (B) Representative confocal micrographs for control and I1 region from patients PNK025 and PNK027 compared to commercially available human normal bladder section (control, US Biomax) with DNA in blue, Mucin in green, COX-2 in red and neutrophils in magenta. Scale bar represents 10 μ m. (C, D) Quantification of COX-2 expressing cells and (D) neutrophils within the urothelium reported as percentage of total urothelial cells. 10 randomly sampled images taken with a 63 $\times$ objective were enumerated for scoring. C denotes control. (E) Bar graphs represent mean $\pm$ SEM (E) Urinary PGE₂ normalized to Cr. (F) Raw urinary PGE₂ concentration. Bar graphs represent mean $\pm$ SD. (G) Linear regression with Spearman's correlation between raw urinary PGE₂ concentration and %COX-2-positive urothelial cells. Red circle denotes positive urine culture. Purple circle denotes PNK025.

al, 2014). These data along with our observed association between urinary PGE₂ and bacterial load led us to hypothesize that urinary PGE₂ may be a biomarker for active rUTI in postmenopausal women. To test this hypothesis, we measured urinary PGE₂ in a third cohort (Cohort 3, n = 92) of postmenopausal women. rUTI patients typically oscillate between rUTI remission and relapse (Dason et al, 2011; Corriere et al, 2013). Accordingly, women were stratified into three groups based on their current infection status and rUTI history: Never (no UTI history), Remission (rUTI history, no current rUTI) and Relapse (rUTI history, current UTI) (Fig 4A). The Never group served as a control for normal variations in urinary PGE₂ levels between individuals. The Remission group allowed determination of COX-2 activity in the absence of active infection in rUTI-sensitized

individuals. None of the women in Cohort 3 were undergoing CFT and active rUTI in the Relapse group was managed by antibiotic therapy. Cohort summary statistics are reported in Table 2.

We observed significantly elevated urinary PGE₂ concentration, both raw and normalized to Cr, in Relapse patients as compared to the Remission and Never patients (Fig 4B and C). The median level of PGE₂ in the Relapse group was 2,318 pg/ml (Interquartile range [IQR]: 1,859–2,879) compared to 1,050 pg/ml (IQR: 464.5–1,675) and 965.1 pg/ml (IQR: 391.9–1,773) in the Remission and Never groups, respectively (Fig 4C). We observed no significant difference in urinary PGE₂ levels between the Remission and Never groups (Fig 4C). These data suggest that during rUTI remission urinary PGE₂

Table 1. Cohort 2 patient characteristics.

Patients	Age (yr)	BMI (kg/m ²)	Diabetes	Prior CFT	Urine culture history	Urine culture before CFT
PNK016	58	32.2	IDDM	No	<i>Pseudomonas aeruginosa</i> and <i>Proteus mirabilis</i>	<i>Enterococcus faecalis</i> (10 ⁵)
PNK017	65	25.3	No	No	<i>P. aeruginosa</i> , <i>Escherichia coli</i> , and <i>E. faecalis</i>	No growth
PNK018	62	24.0	No	No	<i>Klebsiella pneumoniae</i> , <i>E. coli</i> , and <i>E. faecalis</i>	No growth
PNK019	80	22.5	No	No	<i>E. faecalis</i> and <i>K. pneumoniae</i>	No growth
PNK020	51	31.9	No	No	<i>E. coli</i>	No growth
PNK022	88	27.5	No	No	<i>E. coli</i>	No growth
PNK023	82	20.7	No	No	<i>K. pneumoniae</i>	<i>K. pneumoniae</i> (10 ⁵)
PNK024	58	30.9	AODM	Yes	<i>K. pneumoniae</i>	No growth
PNK025	66	41.2	No	No	<i>E. coli</i>	No growth
PNK026	65	35.0	AODM	No	<i>E. coli</i>	No growth
PNK027	77	22.0	No	Yes	<i>E. coli</i> and <i>E. faecalis</i>	<i>Enterococcus faecium</i> (10 ⁵), <i>Aerococcus urinae</i> (55–99,000)

Relevant patient data recorded for the 11 study participants. BMI, body mass index. Diabetes: no, nondiabetic; IDDM, diabetes mellitus type 1; AODM, adult-onset diabetes mellitus type 2; CFT, cystoscopy with fulguration of trigonitis. Urine cultures performed in clinical laboratories with a 10⁴ CFU/ml detection limit.

returns to basal levels; however, longitudinal studies must be conducted to confirm this result.

PGE₂ is a biomarker of active rUTI in postmenopausal women

We then analyzed cohort-associated clinical metadata to identify additional variables associated with group (Never, Remission, Relapse) membership or rUTI status. A total of 16 variables were tested including age, BMI, urine pH, estrogen hormone therapy (EHT), prolapse stage, post void residual (PVR) and diabetes (Tables S1 and S2). Besides urinary PGE₂ concentration ($P < 0.001$) and PGE₂/

Cr ratio ($P < 0.001$), BMI was the only variable significantly associated with group membership ($P = 0.0161$, Fig S5A). PGE₂ concentration, PGE₂/Cr ratio, and BMI were positively associated with active rUTI, whereas EHT ($P = 0.01246$) was negatively associated with active rUTI (Table S1 and Fig S5B). We next used logistic regression to detect biomarkers of rUTI status within the clinical metadata (Fig S6). The PGE₂ logistic regression model outperformed all other single-variable models in predicting rUTI status with an area under the curve (AUC) of 0.841 (Fig 4D and Table 3). Adding the covariates of age, BMI, EHT, PVR, and urine pH improved the model slightly (AUC = 0.880) but PGE₂ was the primary driver of the model

Figure 3. FISH detects bladder-resident bacterial communities.

(A) Representative confocal micrograph of FISH performed on PNK025 and PNK027 I1 biopsies using universal 16S rRNA and scramble probes with bacteria in magenta and DNA in blue. White arrowheads point to bacteria. (B) Violin plot of urothelial and suburothelial bacterial community enumeration in each biopsy. 10 randomly sampled images were quantified per biopsy. Individual data points are open circles and black boxes depict the median.

Figure 4. Urinary PGE₂ is a biomarker for active recurrent urinary tract infection (rUTI) and is the best model to predict rUTI relapse in postmenopausal women. (A) Diagram depicting Cohort 3 design. Patients were stratified into three cohorts: Never (no clinical history of urinary tract infection [UTI]), Remission (history of rUTI, no current UTI), and Relapse (history of rUTI, current UTI). (B, C) Urinary PGE₂ normalized to creatinine and (C) raw urinary PGE₂ concentration as measured by ELISA. P-values generated by Kruskal-Wallis test and Dunn's multiple comparison test. Whiskers drawn to minimum and maximum, boxes represent interquartile range, and median is denoted by a horizontal line. (D) Receiver operating characteristic curves of single-variable logistic regression models illustrate the ability of each model to predict rUTI status. Area under the curve was calculated using leave-one-out cross validation. (E) Receiver operating characteristic curves comparing multivariable logistic regression models to a PGE₂-only model for predicting rUTI. Area under the curve was calculated using leave-one-out cross validation.

as dropping PGE₂ from the model reduced the AUC to 0.805 (Fig 4E and Table 3). Taken together, these results indicate that urinary PGE₂ is a strong predictor, or biomarker, of rUTI status in this cohort of postmenopausal women.

PGE₂ is associated with active rUTI in postmenopausal women with adult-onset diabetes mellitus (AODM)

There is a high frequency (22–33%) of AODM in adults over the age of 65 years in the United States and a high incidence of rUTI in individuals with AODM (Kirkman et al, 2012; Corriere et al, 2013; Nitzan et al, 2015). Therefore, a clinically useful biomarker for rUTI would differentiate patients independent of AODM status. We identified Cohort 3 individuals with AODM and divided patients into groups defined by documented AODM diagnosis and UTI status at the time of urine donation: No active UTI and nondiabetic, Active UTI and nondiabetic, No active UTI and diabetic, and Active UTI and diabetic. Urinary PGE₂ levels were significantly elevated in the Active UTI versus No active UTI in both diabetic and nondiabetic groups (Fig

5A). These results suggest that urinary PGE₂ can be used as a biomarker of rUTI in individuals with and without AODM.

Association between urinary PGE₂ and relevant clinical variables

COX-2-mediated inflammation can be affected by many clinically relevant factors, such as, age, BMI, and the common use of non-steroidal anti-inflammatory drugs (NSAIDs). In contrast to non-selective NSAIDs like ibuprofen, COX-2-selective inhibitors (e.g., Celecoxib) preferentially block COX-2 activity over COX-1 activity and are prescribed to adults for the management of osteoarthritis, rheumatoid arthritis, and acute pain (Schattenkirchner, 1997; Zarghi & Arfaei, 2011; Zweers et al, 2011). We found that 25% of women in Cohort 3 used nonselective or selective NSAIDs (Table 2). To determine if there was any association between NSAID use on urinary PGE₂, we classified Cohort 2 and 3 patients into three groups based upon NSAID use: no NSAID, nonselective NSAID and selective NSAID. We observed no statistically significant difference in urinary PGE₂ concentrations between these groups (Fig S7A). The distribution of

Table 2. Cohort 3 summary statistics.

	Never	Remission	Relapse
Number of women (n)	26	35	31
Hx of fulguration	0	20	19
Median Age (IQR) (yr)	69.5 (63–77.75)	70 (63–81)	74 (70–80)
Median BMI (IQR) (kg/m ²)	26.05 (21.4–27.5)	27.8 (22–31)	27.9 (25.4–32.1)
Median urine pH (IQR)	6 (5–7)	5.82 (5–6.74)	5.35 (5–6)
AODM (%)	1 (3%)	7 (20%)	6 (19.35%)
EHT (%)	14 (53%)	22 (62%)	9 (29%)
NSAID	Selective (%)	5 (14.28%)	1 (3.22%)
	Nonselective (%)	7 (20%)	2 (6.45%)

Median and interquartile range (IQR) for age; (BMI) body mass index, and urinary pH. AODM, adult-onset diabetes mellitus; EHT, estrogen hormone therapy; NSAID, nonsteroidal anti-inflammatory drugs.

specific NSAIDs used by patients in Cohorts 2 and 3 is reported in [Fig S7B](#).

EHT has been shown to affect local immune responses ([Porter et al, 2001](#)). Since EHT is common among postmenopausal women ([Stanton et al, 2020](#)), we evaluated the association between urinary PGE₂ and EHT. Although no association was found between EHT and urinary PGE₂ concentration, only 29% of patients in the Relapse group used EHT compared to 62% and 53% of patients in the Remission and Never groups, respectively, ([Fig S7C](#) and [Table 3](#)). Similarly, no association was found between urinary PGE₂ and urine pH ([Fig S7D](#)), BMI ([Fig S7E](#)), and age ([Fig S7F](#)).

Urinary PGE₂ concentration is predictive of rUTI relapse

To further investigate the association between elevated urinary PGE₂ and rUTI, we recorded time to relapse over a 12-mo period for the Relapse group. We dichotomized patients about the median PGE₂ concentration into above median (n = 15, >2,318 pg/ml) and below median (n = 16, ≤2,318 pg/ml) groups. Proportional hazard analysis using the Mantel–Cox log-rank test indicated a much

higher likelihood of rUTI relapse ($HR_{high/low} = 3.61$, $HR_{low/high} = 0.277$, $P = 0.0087$) in the above median group compared to the below median group ([Fig 5B](#)). At the end of the follow-up period, 12/15 patients in the above median group experienced rUTI relapse versus 5/16 patients in the below median group ([Fig 5B](#)). These data suggest that urinary PGE₂ concentration is predictive of rUTI relapse in this cohort of postmenopausal women.

Discussion

As the human population ages and antimicrobial resistance becomes more widespread, rUTI is becoming both more prevalent and more difficult to manage. Because development of new antibiotics has not kept pace with the rate of emergence of resistant organisms, alternate therapies that improve upon existing antibiotics must be developed ([Gupta et al, 1999](#); [Roca et al, 2015](#)). One strategy is to encourage a more productive immune response by controlling excessive inflammation ([Ingersoll & Albert, 2013](#)). For rUTI, murine

Table 3. Summary of cohort-associated clinical metadata analysis to assess the model prediction accuracy.

Model variables	AUC	F score	Cutoff probability
PGE ₂	0.843	0.778	0.317
Age	0.623	0.574	0.289
Estrogen	0.65	0.564	0.468
BMI	0.627	0.594	0.266
Post void residual (PVR)	0.56	0.504	0.299
pH	0.606	0.538	0.304
PGE ₂ , age, BMI, estrogen, PVR, and pH	0.882	0.761	0.308
PGE ₂ and age	0.844	0.75	0.224
PGE ₂ , age, and estrogen	0.848	0.737	0.268
PGE ₂ , and estrogen	0.855	0.776	0.43
Age, BMI, estrogen, PVR, and pH	0.805	0.675	0.287

Leave-one-out cross-validation (LOOCV) procedure used to calculate the area under the ROC curve (AUC), F-score (predictive accuracy of the model), and the cutoff probability.

Figure 5. High urinary PGE₂ is a prognostic marker for development of recurrent urinary tract infection relapse in a 12-mo follow-up study. (A) Analysis of the urinary PGE₂ concentrations between nondiabetic (filled) and diabetic (empty) No active urinary tract infection (blue circle) versus Active urinary tract infection (red triangle) patients. Mann-Whitney U test used to calculate P-values. (B) Kaplan-Meier analysis of time-to-relapse data for patients in the Relapse group dichotomized about the median PGE₂ concentration. Red line depicts above median and blue line below median patients. Data were analyzed by log-rank (Mantel-Cox) test. HR, hazard ratio (below median/above median) and CI = 95% confidence interval.

studies have identified COX-2-mediated inflammation as a key sensitizing factor and a possible target for alternate rUTI therapies.

In this study, we demonstrate that the product of COX-2, PGE₂, is significantly elevated in the urine of postmenopausal women with active rUTI. Urinary PGE₂ concentration outperformed all other clinical variables as a predictor of rUTI status and was not significantly associated with clinical variables other than active rUTI. These findings suggest that urinary PGE₂ is a reliable biomarker for active rUTI in postmenopausal women. These observations are supported by previous reports of elevated urinary PGE₂ in young patients with UTI before antibiotic therapy (Wheeler et al, 2002). Importantly, we found that elevated PGE₂ concentration was strongly predictive of rUTI relapse in the studied cohort of postmenopausal women.

Previous clinical trials have evaluated the noninferiority of ibuprofen compared to antibiotic therapy, and, although over half

of the ibuprofen treatment cohort recovered without antibiotic therapy, the incidence of complications like pyelonephritis was higher (Gagyor et al, 2015; Vik et al, 2018). Interestingly, neither nonselective COX inhibitors (i.e., ibuprofen) or selective COX-2 inhibitors (i.e., Celecoxib) have been evaluated in conjunction with antibiotics as adjunct therapies for UTI. Our finding that postmenopausal women with above median levels of urinary PGE₂ have a significantly elevated risk of rUTI relapse alongside mechanistic evidence provided by studies in murine models support the hypothesis that high levels of COX-2-mediated inflammation sensitize the bladder to recurrent infection. These findings could be used to inform the design of future clinical trials evaluating the efficacy of adjunct antibiotic and selective COX-2 inhibitor therapies for rUTI.

Materials and Methods

All studies were performed between May 2018 and June 2020 following informed patient consent and institutional review board approval (STU 082010-016, STU 032016-006, MR 17-120).

Cohort 1 and 2 biopsy and urine sample collection

Cold cup biopsies and urine were collected from postmenopausal women under anesthesia undergoing outpatient cystoscopy with fulguration of trigonitis (CFT) for advanced management of antibiotic-refractory rUTI. Exclusion criteria were immunodeficiency, renal insufficiency, urogenital abnormality, and any surgery 1 mo prior. Qualification for antibiotic-refractory rUTI requires presentation of >3 antibiotic class allergies and >3 antibiotic class resistances (Chavez et al, 2020). For Cohort 1, one C1 (no visible cystitis, control) and one I1 (visible cystitis, inflamed) biopsy was obtained (n = 14, PNK001-14) (De Nisco et al, 2019). Cohort 1 patient statistics have been previously reported (De Nisco et al, 2019). For Cohort 2, one I1 biopsy was collected (n = 12, PNK016-27). PNK021 did not pass exclusion criteria. Biopsies were fixed immediately in 4% paraformaldehyde, paraffin-embedded, and longitudinally sectioned using sterile solutions and equipment (De Nisco et al, 2019). Paraffin-embedded normal bladder tissue sections (HUFPT108) were purchased from US Biomax.

Cohort 3 recruitment, urine collection, and classification

92 patients passing exclusion criteria of premenopausal, sporadic UTI, PVR > 150 mL, >stage 2 bladder prolapse, immune suppression, history of catheterization, and surgery less than a month prior were recruited from a tertiary care center into Cohort 3. Clean-catch midstream urine was collected, immediately chilled and processed within 2 h. Urine was handled aseptically and stored in liquid nitrogen. The 92 women were stratified into three groups based on their history of rUTI, UTI symptoms, and urinalysis (UA): Never (no clinical history of symptomatic UTI, n = 26), Remission (history of rUTI, no current UTI symptoms, and -UA, n = 35), and Relapse (history of rUTI, current UTI symptoms, and +UA, n = 31). The women in this cohort were distinct from cohorts 1 and 2 in that their rUTI was not yet refractory to antibiotics and they were therefore not

undergoing CFT. For nonsteroidal anti-inflammatory drug (NSAID) classification, patients taking ibuprofen, aspirin or naproxen were placed in the nonselective NSAID group and patients taking Meloxicam or Celecoxib were placed in the selective NSAID group.

PGE₂ and creatinine measurement

Urinary PGE₂ levels were measured by highly sensitive PGE₂ ELISA (Enzo). To inhibit the activity of prostaglandin synthase, 10 µg/ml indomethacin (Alfa Aesar) was added. PGE₂ ELISA was performed on diluted urine (1:2) and standards. Optical density was measured at 405 nm with a Synergy H1 plate reader (BioTek). PGE₂ concentration was calculated based on the standard curve. Creatinine level was measured in diluted urine (1:20) and standards with the Creatinine Urinary Detection kit (Thermo Fisher Scientific). Absorbance was read at 490 nm and creatinine concentration was calculated based upon the standard curve.

16S rRNA FISH

16S rRNA FISH was performed as described previously (Neugent et al, 2019). Biopsies were fixed immediately upon collection and were processed using sterile reagents and aseptic technique. Briefly, after deparaffinization and rehydration, tissues were incubated with 10 nM Alexa Fluor-647-conjugated probe overnight at 50°C, washed and stained with 1 µg/ml Hoechst (Thermo Fisher Scientific), and mounted.

Immunofluorescence (IF)

Tissues were deparaffinized and rehydrated as described previously (De Nisco et al, 2019). Following antigen retrieval in 10 mM citrate buffer, tissues were blocked in 5% goat serum (Krenacs et al, 2010). IF was performed with primary antibodies against COX-2 (D5H5) 1:500 (rabbit; Cell Signaling) and 2 µg/ml neutrophil elastase (ELA-2, 950334, mouse; Novus). Secondary antibodies Alexa Fluor-555 goat anti-rabbit IgG(H+L) and Alexa Fluor-647 goat anti-mouse IgG(H+L) (Thermo Fisher Scientific) were added to a final concentration of 4 and 2 µg/ml, respectively. Hoechst 33342 final concentration was 1 µg/ml. Alexa Fluor-488 phalloidin and Alexa Fluor-488 Wheat Germ Agglutinin were used at a 1:500 dilution.

Imaging and analysis

For both FISH and IF, confocal micrographs were taken with 63× objectives on a Zeiss LSM880. Images were of a single focal plane and were processed and analyzed with Zen Blue (Zeiss) and ImageJ. 10 randomly sampled images were enumerated from each biopsy section in a blinded manner to calculate the percentage of COX-2 expressing cells and neutrophils present in the urothelium. Cells with a mean fluorescence intensity >10 and integral fluorescence density >1,000 in the Alexa Fluor-555 channel were scored as COX-2 positive. Cells with nuclei surrounded by ELA-2 signal were counted as neutrophils and neutrophils were distinguished from neutrophil extracellular traps by morphology (Brinkmann et al, 2004; Kaplan & Radic, 2012). For 16S rRNA FISH, bacterial communities (Universal 16S rRNA probe) were enumerated in a blinded manner in 10

randomly sampled images taken from a single section of each biopsy and compared with control (Scramble) images taken from the same region of a serial section as previously described (De Nisco et al, 2019).

Time-to-relapse analysis

Time to relapse in the relapse group was assessed by Kaplan–Meier analysis. Patients were dichotomized about the median urinary PGE₂ concentration (n = 16 ≤ median, n = 15 > median). Median PGE₂ was chosen as the discriminator because it is an unbiased method for dichotomizing a group of individuals. Patients were censored at last follow-up time who did not complete a 12-mo follow-up interval (n = 3). The Mantel–Cox log-rank test was performed to test for a time-to-relapse difference between groups.

Statistical analysis

All statistical analyses were performed in GraphPad Prism 8.1.0 and R Studio version 4.0.2 with an α of 0.05. Hypothesis testing was performed using classical methods. Pairwise associations between continuous variables were performed using Spearman's rho correlation with P-values generated by permutation. Differences between continuous variables by group were analyzed using ANOVA or t test if normally distributed, or the Mann–Whitney U test, Wilcoxon matched pairs signed rank test, or Kruskal–Wallis test with multiple comparison post hoc if not normally distributed. Differences between continuous variable by group were analyzed using ANOVA, t test, or Kruskal–Wallis test with multiple comparison post hoc. Differences between categorical variables were analyzed using chi-square, Fisher's exact test, or ordinal logistic regression. Various logistic regression models were constructed to predict rUTI using combinations of all significant covariates. Model fit was assessed using McFadden's pseudo-R². The predictive power of each logistic regression model was assessed using F-scores and AUC attained through leave-one-out cross validation. Models were further compared using ANOVA.

Data Availability

All experimental source data are available upon request from the corresponding author.

Supplementary Information

Supplementary Information is available at <https://doi.org/10.26508/lsa.202000948>.

Acknowledgements

This work was funded in part by the Felecia and John Cain Chair in Women's Health in honor of PE Zimmern, the Welch Foundation grant AT-2030-20200401 (NJ De Nisco), the University of Texas System Rising STARS award (NJ De Nisco), the Welch Foundation grant I-1561 (K Orth), and Once

Upon a Time Foundation (K Orth). K Orth is a Burroughs Wellcome Investigator in Pathogenesis of Infectious Disease, a Beckman Young Investigator, and a W. W. Caruth, Jr., Biomedical Scholar and has an Earl A. Forsythe Chair in Biomedical Science.

Author Contributions

T Ebrahimzadeh: formal analysis, investigation, visualization, methodology, and writing—original draft.

A Kuprasertkul: data curation, investigation, and methodology.

ML Neugent: formal analysis, visualization, methodology, and writing—original draft.

KC Lutz: formal analysis, visualization, methodology, and writing—original draft.

JL Fuentes: data curation and investigation.

J Gadhvi: investigation and visualization.

F Khan: investigation.

C Zhang: formal analysis.

BM Sharon: validation and investigation.

K Orth: funding acquisition and writing—review and editing.

Q Li: conceptualization, supervision, and validation.

PE Zimmern: conceptualization, supervision, funding acquisition, and writing—review and editing.

NJ De Nisco: conceptualization, supervision, funding acquisition, validation, methodology, writing—original draft, and project administration.

Conflict of Interest Statement

The authors declare that they have no conflict of interest.

References

- Amna MA, Chazan B, Raz R, Edelstein H, Colodner R (2013) Risk factors for non-Escherichia coli community-acquired bacteriuria. *Infection* 41: 473–477. doi:10.1007/s15010-012-0347-1
- Bjorling DE, Wang ZY, Bushman W (2011) Models of inflammation of the lower urinary tract. *NeuroUrol Urodyn* 30: 673–682. doi:10.1002/nau.21078
- Brinkmann V, Reichard U, Goosmann C, Fauler B, Uhlemann Y, Weiss DS, Weinrauch Y, Zychlinsky A (2004) Neutrophil extracellular traps kill bacteria. *Science* 303: 1532–1535. doi:10.1126/science.1092385
- Chavez JA, Christie AL, Zimmern PE (2020) Favorable outcomes of repeat electrofulguration procedures in women with antibiotic-refractory recurrent urinary tract infections. *Urology* 146: 83–89. doi:10.1016/j.urology.2020.08.030
- Corriere M, Rooparinesingh N, Kalyani RR (2013) Epidemiology of diabetes and diabetes complications in the elderly: An emerging public health burden. *Curr Diab Rep* 13: 805–813. doi:10.1007/s11892-013-0425-5
- Crivelli JJ, Alhalabi F, Zimmern PE (2019) Electrofulguration in the advanced management of antibiotic-refractory recurrent urinary tract infections in women. *Int J Urol* 26: 662–668. doi:10.1111/iju.13963
- Dason S, Dason JT, Kapoor A (2011) Guidelines for the diagnosis and management of recurrent urinary tract infection in women. *Can Urol Assoc J* 5: 316–322. doi:10.5489/auaj.11214
- De Nisco NJ, Neugent M, Mull J, Chen L, Kuprasertkul A, de Souza Santos M, Palmer KL, Zimmern P, Orth K (2019) Direct detection of tissue-resident bacteria and chronic inflammation in the bladder wall of postmenopausal women with recurrent urinary tract infection. *J Mol Biol* 431: 4368–4379. doi:10.1016/j.jmb.2019.04.008
- Ellis AK, Verma S (2000) Quality of life in women with urinary tract infections: Is benign disease a misnomer? *J Am Board Fam Pract* 13: 392–397. doi:10.3122/15572625-13-6-392
- Flores-Mireles AL, Walker JN, Caparon M, Hultgren SJ (2015) Urinary tract infections: Epidemiology, mechanisms of infection and treatment options. *Nat Rev Microbiol* 13: 269–284. doi:10.1038/nrmicro3432
- Foxman B (2002) Epidemiology of urinary tract infections: Incidence, morbidity, and economic costs. *Am J Med* 113: 5S–13S. doi:10.1016/s0002-9343(02)01054-9
- Foxman B (2014) Urinary tract infection syndromes: Occurrence, recurrence, bacteriology, risk factors, and disease burden. *Infect Dis Clin North Am* 28: 1–13. doi:10.1016/j.idc.2013.09.003
- Gágyor I, Bleidorn J, Kochen MM, Schmiemann G, Wegscheider K, Hummers-Pradier E (2015) Ibuprofen versus fosfomycin for uncomplicated urinary tract infection in women: Randomised controlled trial. *BMJ* 351: h6544. doi:10.1136/bmj.h6544
- Glover M, Moreira CG, Sperandio V, Zimmern P (2014) Recurrent urinary tract infections in healthy and nonpregnant women. *Urol Sci* 25: 1–8. doi:10.1016/j.urols.2013.11.007
- Gupta K, Scholes D, Stamm WE (1999) Increasing prevalence of antimicrobial resistance among uropathogens causing acute uncomplicated cystitis in women. *JAMA* 281: 736–738. doi:10.1001/jama.281.8.736
- Hannan TJ, Mysorekar IU, Hung CS, Isaacson-Schmid ML, Hultgren SJ (2010) Early severe inflammatory responses to uropathogenic E. coli predispose to chronic and recurrent urinary tract infection. *PLoS Pathog* 6: e1001042. doi:10.1371/journal.ppat.1001042
- Hannan TJ, Roberts PL, Riehl TE, van der Post S, Binkley JM, Schwartz DJ, Miyoshi H, Mack M, Schwendener RA, Hooton TM, et al (2014) Inhibition of cyclooxygenase-2 prevents chronic and recurrent cystitis. *EBioMedicine* 1: 46–57. doi:10.1016/j.ebiom.2014.10.011
- Ingersoll MA, Albert ML (2013) From infection to immunotherapy: Host immune responses to bacteria at the bladder mucosa. *Mucosal Immunol* 6: 1041–1053. doi:10.1038/mi.2013.72
- Jancel T, Dudas V (2002) Management of uncomplicated urinary tract infections. *West J Med* 176: 51–55. doi:10.1136/ewj.176.1.51
- Kaplan MJ, Radic M (2012) Neutrophil extracellular traps: Double-edged swords of innate immunity. *J Immunol* 189: 2689–2695. doi:10.4049/jimmunol.1201719
- Kawahara K, Hohjoh H, Inazumi T, Tsuchiya S, Sugimoto Y (2015) Prostaglandin E2-induced inflammation: Relevance of prostaglandin E receptors. *Biochim Biophys Acta* 1851: 414–421. doi:10.1016/j.bbalip.2014.07.008
- Kirkman MS, Briscoe VJ, Clark N, Florez H, Haas LB, Halter JB, Huang ES, Korytkowski MT, Munshi MN, Odegard PS, et al (2012) Diabetes in older adults: A consensus report. *J Am Geriatr Soc* 60: 2342–2356. doi:10.1111/jgs.12035
- Krenacs L, Krenacs T, Stelkovic E, Raffeld M (2010) Heat-induced antigen retrieval for immunohistochemical reactions in routinely processed paraffin sections. *Methods Mol Biol* 588: 103–119. doi:10.1007/978-1-59745-324-0_14
- Lammers AM, van de Kerkhof PC, Schalwijk J, Mier PD (1986) Elastase, a marker for neutrophils in skin infiltrates. *Br J Dermatol* 115: 181–186. doi:10.1111/j.1365-2133.1986.tb05715.x
- Malik RD, Wu YR, Christie AL, Alhalabi F, Zimmern PE (2018a) Impact of allergy and resistance on antibiotic selection for recurrent urinary tract infections in older women. *Urology* 113: 26–33. doi:10.1016/j.urology.2017.08.070
- Malik RD, Wu YR, Zimmern PE (2018b) Definition of recurrent urinary tract infections in women: Which one to adopt? *Female Pelvic Med Reconstr Surg* 24: 424–429. doi:10.1097/SPV.0000000000000509

- Nakanishi M, Rosenberg DW (2013) Multifaceted roles of PGE2 in inflammation and cancer. *Semin Immunopathol* 35: 123–137. doi:[10.1007/s00281-012-0342-8](https://doi.org/10.1007/s00281-012-0342-8)
- Neugent ML, Gadhvi J, Palmer KL, Zimmern PE, De Nisco NJ (2019) Detection of tissue-resident bacteria in bladder biopsies by 16S rRNA fluorescence in situ hybridization. *J Vis Exp* e60458. doi:[10.3791/60458](https://doi.org/10.3791/60458)
- Nicolle LE (2001) A practical guide to antimicrobial management of complicated urinary tract infection. *Drugs Aging* 18: 243–254. doi:[10.2165/00002512-200118040-00002](https://doi.org/10.2165/00002512-200118040-00002)
- Nitzan O, Elias M, Chazan B, Saliba W (2015) Urinary tract infections in patients with type 2 diabetes mellitus: Review of prevalence, diagnosis, and management. *Diabetes Metab Syndr Obes* 8: 129–136. doi:[10.2147/DMSO.S51792](https://doi.org/10.2147/DMSO.S51792)
- O'Brien VP, Hannan TJ, Schaeffer AJ, Hultgren SJ (2015) Are you experienced? Understanding bladder innate immunity in the context of recurrent urinary tract infection. *Curr Opin Infect Dis* 28: 97–105. doi:[10.1097/QCO.0000000000000130](https://doi.org/10.1097/QCO.0000000000000130)
- O'Brien VP, Hannan TJ, Yu L, Livny J, Roberson ED, Schwartz DJ, Souza S, Mendelsohn CL, Colonna M, Lewis AL, et al (2016) A mucosal imprint left by prior *Escherichia coli* bladder infection sensitizes to recurrent disease. *Nat Microbiol* 2: 16196. doi:[10.1038/nmicrobiol.2016.196](https://doi.org/10.1038/nmicrobiol.2016.196)
- Park JY, Pillinger MH, Abramson SB (2006) Prostaglandin E2 synthesis and secretion: The role of PGE2 synthases. *Clin Immunol* 119: 229–240. doi:[10.1016/j.clim.2006.01.016](https://doi.org/10.1016/j.clim.2006.01.016)
- Porter VR, Greendale GA, Schocken M, Zhu X, Effros RB (2001) Immune effects of hormone replacement therapy in post-menopausal women. *Exp Gerontol* 36: 311–326. doi:[10.1016/s0531-5565\(00\)00195-9](https://doi.org/10.1016/s0531-5565(00)00195-9)
- Raz R (2011) Urinary tract infection in postmenopausal women. *Korean J Urol* 52: 801–808. doi:[10.4111/kju.2011.52.12.801](https://doi.org/10.4111/kju.2011.52.12.801)
- Renard J, Ballarini S, Mascarenhas T, Zahran M, Quimper E, Choucair J, Iselin CE (2014) Recurrent lower urinary tract infections have a detrimental effect on patient quality of life: A prospective, observational study. *Infect Dis Ther* 4: 125–135. doi:[10.1007/s40121-014-0054-6](https://doi.org/10.1007/s40121-014-0054-6)
- Ricciotti E, FitzGerald GA (2011) Prostaglandins and inflammation. *Arterioscler Thromb Vasc Biol* 31: 986–1000. doi:[10.1161/ATVBAHA.110.207449](https://doi.org/10.1161/ATVBAHA.110.207449)
- Roca I, Akova M, Baquero F, Carlet J, Cavaleri M, Coenen S, Cohen J, Findlay D, Gyssens I, Heurte OE, et al (2015) The global threat of antimicrobial resistance: Science for intervention. *New Microbes New Infect* 6: 22–29. doi:[10.1016/j.nmni.2015.02.007](https://doi.org/10.1016/j.nmni.2015.02.007)
- Schattenkirchner M (1997) Meloxicam: A selective COX-2 inhibitor non-steroidal anti-inflammatory drug. *Expert Opin Investig Drugs* 6: 321–334. doi:[10.1517/13543784.6.3.321](https://doi.org/10.1517/13543784.6.3.321)
- Stamm WE, Norrby SR (2001) Urinary tract infections: Disease panorama and challenges. *J Infect Dis* 183: S1–S4. doi:[10.1086/318850](https://doi.org/10.1086/318850)
- Stanton A, Mowbray C, Lanz M, Brown K, Hilton P, Tyson-Capper A, Pickard RS, Ali ASM, Hall J (2020) Topical estrogen treatment augments the vaginal response to *Escherichia coli* flagellin. *Sci Rep* 10: 8473. doi:[10.1038/s41598-020-64291-y](https://doi.org/10.1038/s41598-020-64291-y)
- Tang KW, Toh QC, Teo BW (2015) Normalisation of urinary biomarkers to creatinine for clinical practice and research: When and why. *Singapore Med J* 56: 7–10. doi:[10.11622/smedj.2015003](https://doi.org/10.11622/smedj.2015003)
- Vik I, Bollestad M, Grude N, Bærheim A, Damsgaard E, Neumark T, Bjerrum L, Cordoba G, Olsen IC, Lindbæk M (2018) Ibuprofen versus pivmecillinam for uncomplicated urinary tract infection in women—A double-blind, randomized non-inferiority trial. *PLoS Med* 15: e1002569. doi:[10.1371/journal.pmed.1002569](https://doi.org/10.1371/journal.pmed.1002569)
- Wheeler MA, Hausladen DA, Yoon JH, Weiss RM (2002) Prostaglandin E2 production and cyclooxygenase-2 induction in human urinary tract infections and bladder cancer. *J Urol* 168: 1568–1573. doi:[10.1097/01.ju.0000030583.31299.80](https://doi.org/10.1097/01.ju.0000030583.31299.80)
- Wu YR, Rego LL, Christie AL, Lavelle RS, Alhalabi F, Zimmern PE (2016) Recurrent urinary tract infections due to bacterial persistence or reinfection in women—does this factor impact upper tract imaging findings? *J Urol* 196: 422–428. doi:[10.1016/j.juro.2016.01.111](https://doi.org/10.1016/j.juro.2016.01.111)
- Yu L, O'Brien VP, Livny J, Dorsey D, Bandyopadhyay N, Colonna M, Caparon MG, Roberson ED, Hultgren SJ, Hannan TJ (2019) Mucosal infection rewires TNFα signaling dynamics to skew susceptibility to recurrence. *Elife* 8: e46677. doi:[10.7554/eLife.46677](https://doi.org/10.7554/eLife.46677)
- Zarghi A, Arfaei S (2011) Selective COX-2 inhibitors: A review of their structure-activity relationships. *Iran J Pharm Res* 10: 655–683. doi:[10.22037/ijpr.2011.1047](https://doi.org/10.22037/ijpr.2011.1047)
- Zweers MC, de Boer TN, van Roon J, Bijlsma JW, Lafeber FP, Mastbergen SC (2011) Celecoxib: Considerations regarding its potential disease-modifying properties in osteoarthritis. *Arthritis Res Ther* 13: 239. doi:[10.1186/ar3437](https://doi.org/10.1186/ar3437)

License: This article is available under a Creative Commons License (Attribution 4.0 International, as described at <https://creativecommons.org/licenses/by/4.0/>).